02:30 AM EDT, 10/29/2026 (MT Newswires) -- Molecular Partners (MOLN.SW) revised its financial guidance for full-year 2026, according to a Thursday filing. The Swiss biopharmaceutical company now expects total operating expenses of between 50 million francs and 55 million francs, including 5 million francs of non-cash effective costs for share-based payments, IFRS pension accounting, and depreciation. It previously expected operating expenses of between 45 million francs and 55 million francs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.